Literature DB >> 28863009

Methadone and the QTc Interval: Paucity of Clinically Significant Factors in a Retrospective Cohort.

Gavin Bart1, Zachary Wyman, Qi Wang, James S Hodges, Rehan Karim, Bradley A Bart.   

Abstract

OBJECTIVE: Methadone is associated with prolongation of the electrocardiographic QTc interval. QTc prolongation may be linked to cardiac dysrhythmia and sudden cardiac death. The rate of these events is unknown in methadone-maintained patients.
METHODS: This retrospective cohort study of 749 patients with opioid use disorder receiving methadone maintenance therapy through a single safety-net hospital, queried the electronic health record for electrocardiogram results, demographics, methadone dose, and diagnostic codes consistent with cardiac conduction disorder (International Classification of Disease, Ninth Revision [ICD-9] 426) and cardiac dysrhythmia (ICD-9 427). Factors associated with QTc interval were explored; Cox proportional-hazards regression models were used to analyze time to an event that may predispose to sudden cardiac death.
RESULTS: One hundred thirty-four patients had an electrocardiogram while on methadone, 404 while off methadone, and 211 both while on and off methadone. Mean QTc interval while on methadone (436 ms, SD 36) was significantly greater than while off methadone (423 ms, SD 33). Age and methadone dose were weakly associated with increased QTc interval (P < 0.01 and P < 0.0005, respectively, adjusted R = 0.05). There were 44 ICD-9 426 and 427 events over 7064 patient-years (6.3 events/1000 patient-yrs). Having a QTc greater than sex-specific cut-off values was significantly associated with time to event (hazard ratio 3.32, 95% confidence interval 1.25-8.81), but being on methadone was not.
CONCLUSIONS: Methadone is associated with QTc prolongation in a nonclinically significant dose-related manner. Cardiac events were rare and the sudden cardiac death rate was below that of the general population. Current recommendations for cardiac risk assessment in methadone-maintained patients should be reconsidered.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28863009      PMCID: PMC5679071          DOI: 10.1097/ADM.0000000000000353

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  21 in total

1.  Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society.

Authors:  Roger Chou; Ricardo A Cruciani; David A Fiellin; Peggy Compton; John T Farrar; Mark C Haigney; Charles Inturrisi; John R Knight; Shirley Otis-Green; Steven M Marcus; Davendra Mehta; Marjorie C Meyer; Russell Portenoy; Seddon Savage; Eric Strain; Sharon Walsh; Lonnie Zeltzer
Journal:  J Pain       Date:  2014-04       Impact factor: 5.820

2.  Estimating the risk of fatal arrhythmia in patients in methadone maintenance treatment for heroin addiction.

Authors:  Bethany Butler; George Rubin; Anne Lawrance; Robert Batey; James Bell
Journal:  Drug Alcohol Rev       Date:  2011-03

3.  CSAT's QT interval screening in methadone report: outrageous fortune or sea of troubles?

Authors:  Gavin Bart
Journal:  J Addict Dis       Date:  2011-10

Review 4.  Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies.

Authors:  Alicia Montanez; Jeremy N Ruskin; Patricia R Hebert; Gervasio A Lamas; Charles H Hennekens
Journal:  Arch Intern Med       Date:  2004-05-10

5.  Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study.

Authors:  Katinka Anchersen; Thomas Clausen; Michael Gossop; Viggo Hansteen; Helge Waal
Journal:  Addiction       Date:  2009-04-09       Impact factor: 6.526

Review 6.  Long QT syndrome.

Authors:  Ilan Goldenberg; Arthur J Moss
Journal:  J Am Coll Cardiol       Date:  2008-06-17       Impact factor: 24.094

7.  Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes.

Authors:  Mori J Krantz; Ilana B Kutinsky; Alastair D Robertson; Philip S Mehler
Journal:  Pharmacotherapy       Date:  2003-06       Impact factor: 4.705

8.  Prospective study of QTc changes among former opiate addicts since admission to methadone maintenance treatment: benzodiazepine risk.

Authors:  Einat Peles; Shirley Linzy; Mary Jeanne Kreek; Miriam Adelson
Journal:  J Addict Med       Date:  2013 Nov-Dec       Impact factor: 3.702

9.  Prevalence of long QTc interval in methadone maintenance patients.

Authors:  Francina Fonseca; Julio Marti-Almor; Antoni Pastor; Mercè Cladellas; Magí Farré; Rafael de la Torre; Marta Torrens
Journal:  Drug Alcohol Depend       Date:  2008-09-05       Impact factor: 4.492

10.  QT interval prolongation in opioid agonist treatment: analysis of continuous 12-lead electrocardiogram recordings.

Authors:  Geoffrey K Isbister; Amanda L Brown; Anthony Gill; Alexander J Scott; Leonie Calver; Adrian J Dunlop
Journal:  Br J Clin Pharmacol       Date:  2017-06-14       Impact factor: 4.335

View more
  6 in total

1.  Management of opioid use disorder and associated conditions among hospitalized adults: A Consensus Statement from the Society of Hospital Medicine.

Authors:  Susan L Calcaterra; Marlene Martin; Richard Bottner; Honora Englander; Zoe Weinstein; Melissa B Weimer; Eugene Lambert; Shoshana J Herzig
Journal:  J Hosp Med       Date:  2022-07-26       Impact factor: 2.899

Review 2.  How to Use Methadone in an Era of an Opioid Epidemic.

Authors:  Yvonne Heung; Akhila Reddy
Journal:  Curr Treat Options Oncol       Date:  2020-03-19

3.  Integrating in vitro data and physiologically based kinetic modeling-facilitated reverse dosimetry to predict human cardiotoxicity of methadone.

Authors:  Miaoying Shi; Hans Bouwmeester; Ivonne M C M Rietjens; Marije Strikwold
Journal:  Arch Toxicol       Date:  2020-05-04       Impact factor: 5.153

Review 4.  Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine.

Authors:  Florence Noble; Nicolas Marie
Journal:  Front Psychiatry       Date:  2019-01-18       Impact factor: 4.157

5.  Opioid use disorder in pregnancy.

Authors:  Kristin Harter
Journal:  Ment Health Clin       Date:  2019-11-27

6.  Add-On Selective Estrogen Receptor Modulators for Methadone Maintenance Treatment.

Authors:  Chieh-Liang Huang; Yao-Chang Chiang; Wei-Chun Chang; Yu-Ting Su; Juan-Cheng Yang; Wei-Chung Cheng; Hsien-Yuan Lane; Ing-Kang Ho; Wen-Lung Ma
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-05       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.